SI3609886T1 - Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo - Google Patents

Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo

Info

Publication number: SI3609886T1
Authority: SI; Slovenia
Prior art keywords: benzoazepine; bruton; analogues; tyrosine kinase; kinase inhibitors
Prior art date: 2017-04-14

Application number

SI201831083T

Other languages

English (en)

Inventor

Brian T. Hopkins

Bin Ma

Robin Prince

Isaac Marx

Joseph P. Lyssikatos

Fengmei Zheng

Matthew Peterson

Daniel B. Patience

Original Assignee

Biogen Ma Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-14

Filing date

2018-04-13

Publication date

2024-05-31

2018-04-13 Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.

2024-05-31 Publication of SI3609886T1 publication Critical patent/SI3609886T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SI201831083T 2017-04-14 2018-04-13 Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo SI3609886T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762485745P	2017-04-14	2017-04-14
EP18721632.0A EP3609886B1 (en)	2017-04-14	2018-04-13	Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PCT/US2018/027415 WO2018191577A1 (en)	2017-04-14	2018-04-13	Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase

Publications (1)

Publication Number	Publication Date
SI3609886T1 true SI3609886T1 (sl)	2024-05-31

Family

ID=62092333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201831083T SI3609886T1 (sl)	2017-04-14	2018-04-13	Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo

Country Status (37)

Country	Link
US (5)	US10227341B2 (sl)
EP (2)	EP4249071A3 (sl)
JP (3)	JP7145874B2 (sl)
KR (2)	KR20230164247A (sl)
CN (2)	CN110621670B (sl)
AR (2)	AR111594A1 (sl)
AU (3)	AU2018253209B2 (sl)
BR (1)	BR112019021399A2 (sl)
CA (1)	CA3058774A1 (sl)
CL (1)	CL2019002900A1 (sl)
CO (1)	CO2019012571A2 (sl)
CR (2)	CR20190517A (sl)
DK (1)	DK3609886T3 (sl)
EA (1)	EA201992354A1 (sl)
ES (1)	ES2975769T3 (sl)
FI (1)	FI3609886T3 (sl)
HR (1)	HRP20240361T1 (sl)
HU (1)	HUE066253T2 (sl)
IL (3)	IL269933B (sl)
JO (1)	JOP20190233A1 (sl)
LT (1)	LT3609886T (sl)
MA (1)	MA50013B1 (sl)
MD (1)	MD3609886T2 (sl)
MX (1)	MX2023000812A (sl)
PE (2)	PE20200740A1 (sl)
PH (1)	PH12019502334A1 (sl)
PL (1)	PL3609886T3 (sl)
PT (1)	PT3609886T (sl)
RS (1)	RS65386B1 (sl)
SA (1)	SA519410292B1 (sl)
SG (1)	SG11201909224QA (sl)
SI (1)	SI3609886T1 (sl)
SM (1)	SMT202400166T1 (sl)
TW (2)	TWI790227B (sl)
UA (1)	UA127347C2 (sl)
WO (1)	WO2018191577A1 (sl)
ZA (1)	ZA202306172B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2932608C (en)	2013-12-11	2023-02-14	Biogen Ma Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JOP20190233A1 (ar)	2017-04-14	2019-10-02	Biogen Ma Inc	نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
JP7476214B2 (ja) *	2018-10-15	2024-04-30	バイオジェン・エムエイ・インコーポレイテッド	ブルトン型チロシンキナーゼ阻害剤の結晶多形
DE112019004803T5 (de)	2018-10-22	2021-07-08	Murata Manufacturing Co., Ltd.	Ventil und gassteuervorrichtung
WO2020232330A1 (en) *	2019-05-15	2020-11-19	Biogen Ma Inc.	Inhibiting agents for bruton's tyrosine kinase
WO2022140246A1 (en)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
WO2022212893A1 (en)	2021-04-02	2022-10-06	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
JP2024544529A (ja)	2021-11-10	2024-12-03	バイオジェン・エムエイ・インコーポレイテッド	Ｂｔｋ阻害剤
JP2023140319A (ja)	2022-03-22	2023-10-04	アッヴィ・インコーポレイテッド	ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245577A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
WO2008116064A2 (en)	2007-03-21	2008-09-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
KR101701109B1 (ko)	2007-10-05	2017-02-13	베라스템, 인코포레이티드	피리미딘 치환된 퓨린 유도체
EP2253618A1 (en)	2008-02-27	2010-11-24	Takeda Pharmaceutical Company Limited	Compound having 6-membered aromatic ring
KR101892989B1 (ko)	2008-06-27	2018-08-30	셀젠 카르 엘엘씨	헤테로아릴 화합물 및 이의 용도
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
PT2473049T (pt) *	2009-09-04	2019-03-04	Sunesis Pharmaceuticals Inc	Inibidores de tirosina quinase de bruton
US8334292B1 (en)	2010-06-14	2012-12-18	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
BR112014001255B1 (pt)	2011-07-19	2019-07-02	Merck Sharp & Dohme B.V.	Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
TWI638815B (zh) *	2013-02-15	2018-10-21	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺類（一）
US20140357636A1 (en)	2013-02-21	2014-12-04	Wayne Rothbaum	Treatment of Skeletal-Related Disorders
MX2016005054A (es)	2013-10-21	2016-07-19	Merck Patent Gmbh	Compuestos heteroarilo como inhibidores de tirosina cinasa de bruton (bkt) y usos de los mismos.
CA2932608C (en)	2013-12-11	2023-02-14	Biogen Ma Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2015328285B2 (en) *	2014-10-06	2019-07-18	Merck Patent Gmbh	Heteroaryl compounds as BTK inhibitors and uses thereof
JOP20190233A1 (ar)	2017-04-14	2019-10-02	Biogen Ma Inc	نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

2017
- 2017-06-16 JO JOP/2019/0233A patent/JOP20190233A1/ar unknown
2018
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 KR KR1020237040706A patent/KR20230164247A/ko active Pending
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/en active Application Filing
- 2018-04-13 HU HUE18721632A patent/HUE066253T2/hu unknown
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 BR BR112019021399A patent/BR112019021399A2/pt active Search and Examination
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-04-13 RS RS20240419A patent/RS65386B1/sr unknown
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active Active
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/en active Pending
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 TW TW111149550A patent/TWI846229B/zh active
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 IL IL294175A patent/IL294175B1/en unknown
- 2018-04-13 ES ES18721632T patent/ES2975769T3/es active Active
- 2018-04-13 PL PL18721632.0T patent/PL3609886T3/pl unknown
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 PE PE2024000228A patent/PE20240930A1/es unknown
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 SM SM20240166T patent/SMT202400166T1/it unknown
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 MA MA50013A patent/MA50013B1/fr unknown
- 2018-04-13 CA CA3058774A patent/CA3058774A1/en active Pending
- 2018-04-13 IL IL316713A patent/IL316713A/en unknown
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/en active Active
- 2018-04-13 PT PT187216320T patent/PT3609886T/pt unknown
- 2018-04-13 HR HRP20240361TT patent/HRP20240361T1/hr unknown
- 2018-04-13 SI SI201831083T patent/SI3609886T1/sl unknown
- 2018-04-13 MD MDE20200193T patent/MD3609886T2/ro unknown
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
2019
- 2019-04-13 CR CR20230539A patent/CR20230539A/es unknown
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP7581294B2/ja active Active
2023
- 2023-06-12 ZA ZA2023/06172A patent/ZA202306172B/en unknown
- 2023-06-15 AR ARP230101541A patent/AR129632A2/es unknown
2024
- 2024-06-20 AU AU2024204241A patent/AU2024204241A1/en active Pending
- 2024-10-30 JP JP2024190472A patent/JP2025020247A/ja active Pending

Also Published As

Publication number	Publication date
KR20230164247A (ko)	2023-12-01
TWI846229B (zh)	2024-06-21
EP4249071A2 (en)	2023-09-27
US10189829B2 (en)	2019-01-29
CN110621670B (zh)	2023-09-15
DK3609886T3 (da)	2024-03-18
MA50013A (fr)	2020-07-08
US20230147490A1 (en)	2023-05-11
CL2019002900A1 (es)	2020-01-24
AU2022218560B2 (en)	2024-04-04
AU2024204241A1 (en)	2024-07-11
ES2975769T3 (es)	2024-07-15
TW202315870A (zh)	2023-04-16
PH12019502334A1 (en)	2020-09-21
IL294175B1 (en)	2024-12-01
SMT202400166T1 (it)	2024-07-09
SA519410292B1 (ar)	2023-03-12
JP2025020247A (ja)	2025-02-12
ZA202306172B (en)	2024-11-27
JP2020516659A (ja)	2020-06-11
IL269933A (sl)	2019-11-28
AU2022218560A1 (en)	2022-09-15
PL3609886T3 (pl)	2024-05-13
CN110621670A (zh)	2019-12-27
AU2018253209B2 (en)	2022-06-02
US10227341B2 (en)	2019-03-12
EA201992354A1 (ru)	2020-03-10
RS65386B1 (sr)	2024-04-30
MA50013B1 (fr)	2024-05-31
PT3609886T (pt)	2024-04-11
JP2022180498A (ja)	2022-12-06
CA3058774A1 (en)	2018-10-18
HRP20240361T1 (hr)	2024-06-07
US20210340135A1 (en)	2021-11-04
FI3609886T3 (fi)	2024-03-26
MD3609886T2 (ro)	2024-07-31
BR112019021399A2 (pt)	2020-04-28
LT3609886T (lt)	2024-04-10
CO2019012571A2 (es)	2020-01-17
EP4249071A3 (en)	2024-01-24
US10961237B2 (en)	2021-03-30
WO2018191577A1 (en)	2018-10-18
TW201841909A (zh)	2018-12-01
CR20190517A (es)	2020-02-13
KR20190139926A (ko)	2019-12-18
US20200239459A1 (en)	2020-07-30
US11427577B2 (en)	2022-08-30
IL316713A (en)	2024-12-01
PE20200740A1 (es)	2020-07-24
KR102607900B1 (ko)	2023-11-29
JOP20190233A1 (ar)	2019-10-02
US20180297992A1 (en)	2018-10-18
TWI790227B (zh)	2023-01-21
SG11201909224QA (en)	2019-11-28
AR129632A2 (es)	2024-09-11
EP3609886B1 (en)	2024-02-07
IL294175A (en)	2022-08-01
AU2018253209A1 (en)	2019-10-31
AR111594A1 (es)	2019-07-31
PE20240930A1 (es)	2024-04-30
JP7581294B2 (ja)	2024-11-12
US20180362522A1 (en)	2018-12-20
US11858926B2 (en)	2024-01-02
IL269933B (en)	2022-07-01
EP3609886A1 (en)	2020-02-19
UA127347C2 (uk)	2023-07-26
CR20230539A (es)	2024-04-08
MX2023000812A (es)	2023-02-27
JP7145874B2 (ja)	2022-10-03
CN117567453A (zh)	2024-02-20
HUE066253T2 (hu)	2024-07-28

Publication	Publication Date	Title
SI3609886T1 (sl)	2024-05-31	Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
ZA201903932B (en)	2021-01-27	Imidazopyrazine inhibitors of bruton's tyrosine kinase
ZA201907661B (en)	2022-08-31	Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
IL255831A (en)	2018-01-31	Inhibitors of bruton's tyrosine kinase
HK1256857A1 (zh)	2019-10-04	多氟化合物作為布魯頓酪氨酸激酶抑制劑
ZA201805439B (en)	2019-11-27	Bruton's tyrosine kinase inhibitors
MA45937A (fr)	2019-06-19	Inhibiteurs d'amino pyrimidine ssao
HK1258699A1 (zh)	2019-11-15	包含酪氨酸蛋白激酶抑制劑的劑型組合物
HK1243929A1 (zh)	2018-07-27	Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合
MA43162A (fr)	2018-09-12	Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
EP3174539A4 (en)	2017-12-13	Inhibitors of bruton's tyrosine kinase
ZA201906887B (en)	2022-03-30	Bruton's tyrosine kinase inhibitors
IL259863B (en)	2020-06-30	Polycyclic compounds as inhibitors of proton tyrosine kinase
EP3141546A4 (en)	2018-01-10	Inhibitor of bruton's tyrosine kinase
MA41350A (fr)	2017-11-21	Synthèse d'un inhibiteur de la tyrosine kinase de bruton
ZA201903694B (en)	2021-04-28	Inhibitors of bruton's tyrosine kinase
EP3159340A4 (en)	2018-02-21	New bruton's tyrosine kinase inhibitor
MA52629A (fr)	2021-03-24	Agents inhibiteurs de la tyrosine kinase de bruton
MA41643A (fr)	2018-01-09	Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
TH1401007217A (th)	2016-11-07	รูปแบบชนิดผลึกของตัวยับยั้งไทโรซีนไคเนสชนิดบรูตัน